General Drug Use-results Survey of Rituxan Intravenous Infusion - Systemic Sclerosis -

JRCT ID: jRCT2031210659

Registered date:10/03/2022

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Systemic sclerosis
• Date of first enrollment: 10/03/2022
• Target sample size: 400
• Study type: Observational

Outcome(s)

Primary Outcome

Incidence of adverse events and adverse drug reactions.
Clinical global Impression - improvement, patient global Impression - improvement.

Key inclusion & exclusion criteria

• Age minimum: Not applicable
• Age maximum: Not applicable
• Gender: Both
• Include criteria: Patients with systemic sclerosis who have received Rituxan intravenous infusion.
• Exclude criteria: None

Related Information

• Primary Sponsor: Ando Takashi